GSK PLC Sponsored ADR $GSK Holdings Reduced by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lowered its position in GSK PLC Sponsored ADR (NYSE:GSK) by 29.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 605,665 shares of the pharmaceutical company’s stock after selling 248,666 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in GSK were worth $33,427,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. First Horizon Corp boosted its position in shares of GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 236 shares during the period. Elyxium Wealth LLC bought a new position in GSK in the 4th quarter worth approximately $30,000. Triumph Capital Management bought a new position in GSK in the 3rd quarter worth approximately $40,000. 1248 Management LLC increased its position in GSK by 314.6% in the 3rd quarter. 1248 Management LLC now owns 1,053 shares of the pharmaceutical company’s stock valued at $46,000 after acquiring an additional 799 shares during the period. Finally, Coston McIsaac & Partners increased its position in GSK by 17.3% in the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock valued at $68,000 after acquiring an additional 206 shares during the period. Institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GSK. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a research note on Saturday, May 30th. Royal Bank Of Canada reissued an “outperform” rating on shares of GSK in a research note on Tuesday, June 9th. Finally, Weiss Ratings lowered GSK from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 11th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $53.00.

GSK Stock Up 0.2%

GSK stock opened at $50.76 on Friday. The firm’s 50-day moving average is $52.66 and its two-hundred day moving average is $52.82. The company has a market capitalization of $102.80 billion, a price-to-earnings ratio of 13.19, a price-to-earnings-growth ratio of 2.62 and a beta of 0.36. GSK PLC Sponsored ADR has a 52 week low of $35.45 and a 52 week high of $61.69. The company has a current ratio of 0.79, a quick ratio of 0.52 and a debt-to-equity ratio of 0.80.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Investors of record on Friday, May 15th will be paid a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date is Friday, May 15th. GSK’s dividend payout ratio (DPR) is currently 47.01%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.